Advertisement
ALLO vs ARRY
Which Stock Would AI Choose? Allogene Therapeutics (ALLO) vs. Array Technologies (ARRY) Stock Comparison
Key Takeaways
- Allogene Therapeutics (ALLO) is a clinical-stage biotech advancing "off-the-shelf" allogeneic CAR T cell therapies, while Array Technologies (ARRY) is a commercial manufacturer of solar tracking systems for utility-scale projects.
- ALLO's recent performance has been driven by positive trial data for its lead candidate, cema-cel, while ARRY has posted record order-book growth despite pressure on its share price in recent weeks.
- The two companies carry very different risk profiles: ALLO is pre-revenue with clinical and cash-burn risk, whereas ARRY is profitable but exposed to solar industry pricing and policy uncertainty.
- ALLO trades with a smaller market capitalization and heightened volatility typical of development-stage biotech, while ARRY trades at a comparatively low forward price-to-earnings (P/E) multiple.
- Relative performance and market positioning diverge sharply between the two names, reflecting their distinct sectors (healthcare versus energy/industrials) and growth catalysts.
- For deeper coverage, explore ALLO Major News and ALLO Today's Price Move, plus ARRY Major News and ARRY Today's Price Move.
- To see how AI-driven strategies are currently navigating this market, explore Trending AI Robots.
Introduction
This stock comparison pairs two companies that occupy very different corners of the market, yet both attract traders seeking high-conviction, catalyst-driven opportunities. ALLO is a development-stage biotechnology firm whose valuation hinges on clinical trial outcomes, while ARRY is an established industrial manufacturer whose fortunes track utility-scale solar demand. Investors focused on biotech catalysts and long-term clinical upside may find ALLO compelling, whereas those seeking revenue-generating operations and value-style metrics may gravitate toward ARRY. Comparing their relative performance and market positioning illustrates how different risk and reward profiles can coexist in the same market environment.
ALLO Overview and Recent Performance
Allogene Therapeutics develops "off-the-shelf" allogeneic CAR T cell therapies — engineered immune cells derived from healthy donors rather than a patient's own cells — for cancer and autoimmune diseases. Its lead candidate, cema-cel, is being evaluated in the pivotal Phase 2 ALPHA3 trial for first-line large B-cell lymphoma (LBCL). In recent months, interim data showed a 58.3% rate of minimal residual disease (MRD) negativity at day 45 versus 16.7% for observation, with no treatment-related serious adverse events reported at the cutoff. The company has also received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA).
Sentiment has been shaped by both this clinical progress and financial discipline: ALLO ended its most recent quarter with roughly $423.6 million in cash and investments, which management expects to fund operations into 2029. Despite these advances, the stock has experienced notable volatility and a pullback in recent weeks, trading well below its 52-week high. As a pre-revenue company, ALLO's performance remains tied to data readouts, regulatory milestones, and continued cash-burn management.
ARRY Overview and Recent Performance
Array Technologies is a global manufacturer of ground-mounted solar tracking systems that help utility-scale solar panels follow the sun to maximize energy output. The company has broadened its platform through acquisitions, adding engineered foundations, cable management, and software to its offerings. In its most recent quarter, ARRY reported record order-book levels of approximately $2.5 billion, up 37% year over year, alongside a trailing 12-month book-to-bill ratio of about 1.5x, indicating strong demand for its products.
Despite this operational momentum, ARRY's share price has declined meaningfully in recent weeks, and the stock trades below levels seen earlier in the year. Investors have weighed near-term headwinds including project timing, a shift toward international mix, input costs, and policy uncertainty around tariffs. The company reaffirmed full-year revenue guidance while raising margin expectations, yet near-term revenue cadence and cash-flow conversion remain key watchpoints. ARRY's forward P/E ratio is notably lower than its industry average, reflecting the market's cautious stance toward solar-sector fundamentals.
Trending AI Robots
Tickeron maintains a large library of AI trading bots, spanning hundreds of automated strategies that trade thousands of different tickers across diverse timeframes, sectors, and risk profiles. Because not every bot is suited to every market regime, Tickeron curates only the strongest performers into its Trending AI Robots section — a focused list of the strategies currently best aligned with prevailing market conditions. These bots differ in trading style, strategy, holding period, performance metrics, and the specific sets of tickers they follow, giving traders a range of approaches to evaluate rather than a one-size-fits-all solution. If you are interested in how algorithmic strategies are positioning themselves in today's market, consider exploring the Trending AI Robots page to review the currently featured bots.
Head-to-Head Comparison
The most fundamental contrast between these two stocks is business-model maturity. ALLO generates minimal revenue and depends on clinical validation and eventual regulatory approval, while ARRY is an operating business with hundreds of millions of dollars in quarterly revenue and a growing order book. This translates into divergent risk profiles: ALLO carries binary, event-driven risk around trial readouts, whereas ARRY faces cyclical and policy-driven risk tied to solar project economics and tariffs.
Growth drivers also differ. ALLO's upside is concentrated in cema-cel and its earlier-stage autoimmune program, where positive data could meaningfully re-rate the stock. ARRY's growth depends on book-to-bill momentum, margin expansion, and successful integration of recent acquisitions. From a sentiment standpoint, both stocks have faced recent selling pressure, but ALLO has benefited from a string of positive clinical catalysts, while ARRY's strong fundamentals have not yet translated into sustained share-price momentum. Sector exposure is another key differentiator: ALLO sits in biotechnology and is sensitive to clinical and regulatory news, whereas ARRY belongs to the solar/industrials complex and reacts to energy policy and interest-rate dynamics.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst quality, Tickeron's AI would likely treat these names quite differently. ARRY offers more measurable fundamentals — revenue, margins, and a record order book — but its recent price action has shown weaker trend consistency, which automated trend-following models often penalize. ALLO presents a clearer recent catalyst narrative with favorable clinical data and an extended cash runway, though its pre-revenue status and elevated volatility introduce greater instability. On balance, the AI would likely favor the name with stronger relative momentum and a more defined near-term catalyst set, while acknowledging that both stocks carry meaningful, though very different, risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and ARRY is a Hold.
ALLO in -15.09% downward trend, sliding for three consecutive days on November 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALLO declined for three days, in 283 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The Aroon Indicator for ALLO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 185 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.824) is normal, around the industry mean (3.498). P/E Ratio (-1.576) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for ARRY turns positive, indicating new upward trend
ARRY saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 75 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARRY just turned positive on October 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
ARRY moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARRY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +40.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARRY moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 19 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 47 cases where ARRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.462) is normal, around the industry mean (2.537). P/E Ratio (-6.099) is within average values for comparable stocks, (6.086). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
ALLO | ARRY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 88 | 59 | |
P/E GROWTH RATING 1..100 | 12 | 43 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (8) in the Biotechnology industry is somewhat better than the same rating for ALLO (48). This means that ARRY’s stock grew somewhat faster than ALLO’s over the last 12 months.
ARRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that ARRY’s stock grew similarly to ALLO’s over the last 12 months.
ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as ARRY (100). This means that ALLO’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's Price Growth Rating (59) in the Biotechnology industry is in the same range as ALLO (88). This means that ARRY’s stock grew similarly to ALLO’s over the last 12 months.
ALLO's P/E Growth Rating (12) in the Biotechnology industry is in the same range as ARRY (43). This means that ALLO’s stock grew similarly to ARRY’s over the last 12 months.
| ALLO | ARRY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| Advances ODDS (%) | 9 days ago 81% | 9 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 3 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALLO’s FA Score shows that 1 FA rating(s) are green while ARRY’s FA Score has 1 green FA rating(s).
- ALLO’s FA Score: 1 green, 4 red.
- ARRY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALLO’s TA Score shows that 4 TA indicator(s) are bullish while ARRY’s TA Score has 5 bullish TA indicator(s).
- ALLO’s TA Score: 4 bullish, 4 bearish.
- ARRY’s TA Score: 5 bullish, 5 bearish.
Price Growth
ALLO (@Biotechnology) experienced а -24.36% price change this week, while ARRY (@Alternative Power Generation) price change was -2.44% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was -1.24%. For the same industry, the average monthly price growth was -8.72%, and the average quarterly price growth was -45.95%.
Reported Earning Dates
ALLO is expected to report earnings on Mar 18, 2027.
ARRY is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Alternative Power Generation (-1.24% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
Advertisement
ALLO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALLO | 1D Price Change % | ||
|---|---|---|---|---|
| ALLO | 100% | -3.41% | ||
| EDIT - ALLO | 49% Loosely correlated | -4.99% | ||
| AXON - ALLO | 44% Loosely correlated | +4.26% | ||
| RCKT - ALLO | 43% Loosely correlated | +1.22% | ||
| ARRY - ALLO | 43% Loosely correlated | +9.94% | ||
| FDMT - ALLO | 43% Loosely correlated | +4.25% | ||
More | ||||
ARRY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARRY has been closely correlated with NXT. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARRY jumps, then NXT could also see price increases.
| Ticker / NAME | Correlation To ARRY | 1D Price Change % | ||
|---|---|---|---|---|
| ARRY | 100% | +9.94% | ||
| NXT - ARRY | 67% Closely correlated | +0.77% | ||
| SHLS - ARRY | 63% Loosely correlated | +8.24% | ||
| AXON - ARRY | 53% Loosely correlated | +4.26% | ||
| INO - ARRY | 52% Loosely correlated | +1.72% | ||
| ADPT - ARRY | 50% Loosely correlated | +1.98% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PLTU | 45.59 | 1.86 | +4.25% |
| Direxion Daily PLTR Bull 2X ETF (PLTU) | |||
| VT | 156.71 | 1.77 | +1.14% |
| Vanguard Total World Stock ETF (VT) | |||
| ZAPR | 27.17 | 0.05 | +0.18% |
| Innovator 1 Yr April (ZAPR) | |||
| SHYM | 21.94 | 0.02 | +0.09% |
| iShares Short Duration High Yield Muni Active ETF (SHYM) | |||
| BOXA | 104.58 | N/A | N/A |
| Alpha Architect Aggregate Bond ETF | |||